Clinical trial
Olaparib as Salvage Treatment for Cisplatin-resistant Germ Cell Tumor
NCT02533765 is registered in ClinicalTrials.gov with Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Olaparib as Salvage Treatment for Cisplatin-resistant Germ Cell Tumor
- Lead sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 11, 2015
- Completion date
- February 13, 2023
- Enrollment
- 18 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.